Solventum Corporation $SOLV Shares Sold by Factorial Partners LLC

Factorial Partners LLC cut its stake in Solventum Corporation (NYSE:SOLV) by 22.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,500 shares of the company’s stock after selling 9,500 shares during the period. Solventum accounts for about 1.7% of Factorial Partners LLC’s portfolio, making the stock its 25th largest position. Factorial Partners LLC’s holdings in Solventum were worth $2,575,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of SOLV. Independent Franchise Partners LLP boosted its stake in Solventum by 27.2% in the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after purchasing an additional 2,758,174 shares in the last quarter. Norges Bank acquired a new stake in Solventum in the 4th quarter worth approximately $147,467,000. Diamond Hill Capital Management Inc. boosted its stake in Solventum by 152.2% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after purchasing an additional 1,272,921 shares in the last quarter. Boston Partners raised its position in Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after buying an additional 867,837 shares during the last quarter.

Analysts Set New Price Targets

SOLV has been the subject of a number of recent research reports. Wedbush initiated coverage on shares of Solventum in a research report on Friday, May 15th. They set an “outperform” rating and a $94.00 price target for the company. UBS Group lowered shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a research report on Thursday, May 14th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price target for the company. BTIG Research reissued a “buy” rating and set a $89.00 price target on shares of Solventum in a research report on Wednesday, May 6th. Finally, KeyCorp raised their price target on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Trading Up 1.4%

SOLV stock opened at $75.97 on Tuesday. The company’s 50-day simple moving average is $69.75 and its 200-day simple moving average is $75.08. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.20. The firm has a market cap of $13.16 billion, a P/E ratio of 9.31, a PEG ratio of 1.16 and a beta of 0.59.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the company posted $1.34 EPS. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.24% of the company’s stock.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.